This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

Volume: 5, Issue: 11, Pages: e2241451 - e2241451
Published: Nov 10, 2022
Abstract
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches.To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS.A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group superiority design from June 2015 to August 2017....
Paper Details
Title
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome
Published Date
Nov 10, 2022
Volume
5
Issue
11
Pages
e2241451 - e2241451
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.